Article Details

Aclaris Therapeutics' IND for ATI-052 candidate granted FDA clearance | Markets Insider

Retrieved on: 2025-04-22 18:12:46

Tags for this article:

Click the tags to see associated articles and topics

Aclaris Therapeutics' IND for ATI-052 candidate granted FDA clearance | Markets Insider. View article details on hiswai:

Excerpt

... monoclonal antibody. The Phase ... This dual binding and pathway inhibition potentially enhances efficacy over traditional monoclonal antibodies ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up